GHK-Cu Tissue Remodeling: How It Works at the Cellular Level

Published research reports that GHK-Cu is associated with tissue remodeling through collagen synthesis, anti-inflammatory signaling, and stem cell activation pathways. This article summarizes what the cellular and preclinical literature reports.

What Is GHK-Cu?

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper tripeptide that has been measured in human plasma, saliva, and urine. Published data report that its endogenous concentration declines with age, by roughly 60% between age 20 and 60. In laboratory work, GHK-Cu has been reported to influence collagen and elastin synthesis, copper transport, wound healing models, and inflammatory signaling.

It is one of the most widely studied peptides in the copper peptide class, with research spanning collagen biology, wound healing models, hair-growth assays, and tissue repair. Throughout this page, "copper peptide" refers to laboratory and published findings, not to a product offered for human use.

Cellular Mechanisms Reported in the Literature

Tissue remodeling research reports several cellular mechanisms for GHK-Cu. In fibroblast cultures it has been associated with increased collagen and elastin production. In inflammatory models it has been reported to modulate cytokine signaling and antioxidant response. Stem cell activation — the recruitment and differentiation of progenitor cells in laboratory models — is the third mechanism the literature describes, alongside copper transport to cells.

Routes described in the published research include topical preparations and systemic administration in animal and in-vitro studies. Reported topical concentrations in cosmetic research typically fall in the 3-5% range. Reported parenteral amounts in animal studies have generally been in the 1-2 mg per day range. These figures are cited as reported study parameters from published research, not as a schedule for anyone to follow.

Evidence Base

GHK-Cu has an extensive published literature, anchored by the gene expression study reporting modulation of over 4,000 human genes. A Phase 2 wound healing trial adds clinical-stage data to the preclinical body of work, and the copper peptide collagen research underpins much of the current skin repair and wound healing literature.

GHK-Cu is investigational in the systemic applications discussed here. It is not approved for human use by any regulator, no approved dosing exists, and the amounts above are reported from published research as data points — not as a protocol for anyone to follow.

📊 Dosage Calculator & Protocol Chart

Convert reported research quantities into solution volumes for lab reference:

👉 GHK-Cu Calculator — Concentration and volume conversions for reported research quantities.

👉 Full GHK-Cu Research Overview — The published remodeling data, the Phase 2 trial findings, and the reported study parameters in one place.

Important Disclaimer

This article is for educational and research purposes only. GHK-Cu is investigational in the applications discussed here and has not been approved by the FDA or any other regulator for human use; no approved dosing exists. The information provided here is synthesized from published research, clinical trial data, and community discussions. Nothing on this page is medical advice, and no substance discussed here is offered for human use.

Keywords: GHK-Cu, copper peptide, collagen, wound healing, skin repair

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content